Description: Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-In-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Lag 3 inhibitor) Administered Alone or in Combination with REGN2810 (PD-1 inhibitor) in Patients with Advanced Malignancies.
Target Patient Population: Currently enrolling expansion cohorts in PD-1 naïve metastatic melanoma and metastatic Cutaneous Squamous Cell Cancers (PD1 experienced/naïve)
Study Design: Drug is administered IV every 3 weeks.